BackPacific Biosciences of California Overview

Pacific Biosciences of California Net Tangible Assets

Latest net tangible assets for PACB: $-33M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$-33.21M
154.01% YoYΔ $-94.70M vs prior year quarter

Peer average

Loading

Pacific Biosciences of California Net Tangible Assets History

Loading

Pacific Biosciences of California vs. peers: Net Tangible Assets Comparison

Loading

Pacific Biosciences of California Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Pacific Biosciences of California (PACB) FAQ

As of the most recent data (June 2026), PACB shows a net tangible assets of $-33M. That compares with $61M in the prior-year period — down 154.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PACB's net tangible assets is now $-33M (was $61M) — a 154.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Pacific Biosciences of California is outperforming or lagging.

Tracking PACB's net tangible assets over time shows whether Pacific Biosciences of California is scaling, shrinking, or reshaping that part of the business. The current reading is $-33M That compares with $61M in the prior-year period — down 154.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Pacific Biosciences of California's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $-33M) with ownership activity and broader fundamentals.

Pacific Biosciences of California's net tangible assets is $-33M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.